Improving Lives Through

Innovative Diagnostic Solutions

AXIM is an international healthcare solutions company targeting oncological, COVID-19 and dry eye disease (DED) diagnostics solutions

Improving Lives Through

Innovative Diagnostic Solutions

AXIM is an international healthcare solutions company targeting oncological, COVID-19 and dry eye disease (DED) diagnostics solutions

COVID-19 TESTING

AXIM Biotechnologies has developed the first rapid (10-minute) point-of-care test that measures the concentration of neutralizing antibodies to COVID-19.

AXIM EYE

AXIM looks to assist doctors in diagnosing dry eye disease (DED) faster and more efficiently than alternative methods.  

CANCER dIAGNOSTICS

AXIM is in development of various “point-of-care” diagnostic testing products designed for the early detection of cancer

The Latest On Our Research

Founded in 2014, AXIM® Biotechnologies, Inc. (AXIM) is a vertically integrated research and development company focused on changing the landscape of diagnosis of SARS-CoV-2 (COVID-19), dry eye disease (DED) and Oncological indications. AXIM’s COVID-19 neutralizing antibody test is the first rapid diagnostic test measuring levels of functional neutralizing antibodies that are believed to prevent SARS-CoV-2 from entering the host cells. Additionally, the Company is developing rapid diagnostic tests for the early detection of cancer and ophthalmological conditions such as DED.